afatinib therapy for uncommon egfr alterations in nsclc
Published 5 years ago • 431 plays • Length 3:47Download video MP4
Download video MP3
Similar videos
-
3:30
osimertinib for uncommon egfr mutations in nsclc
-
1:47
dr. west on fda approval of afatinib in nsclc with rare egfr mutations
-
4:06
afatinib in patients with uncommon egfr mutations
-
4:09
frontline afatinib in egfr-mutant nsclc
-
8:47
study of 693 nsclc patients treated with afatinib
-
6:28
sequential treatment with afatinib and osimertinib in patients with egfr mutation-positive nsclc
-
5:47
egfr tkis for upfront treatment of nsclc
-
1:25
dr. chachoua on afatinib for exon 19 mutation in lung cancer
-
6:36
a new treatment option for uncommon egfr mutations (bmic-023)
-
3:59
osimertinib for egfr t790m resistance mutations in nsclc
-
8:38
afatinib plus cetuximab in resistant non-small cell lung cancer
-
6:46
selecting a first-line egfr inhibitor in nsclc
-
3:07
efficacy and safety of afatinib vs erlotinib and gefitinib in egfr nsclc
-
2:34
afatinib: dose modifications and adverse events
-
17:27
how, when, and where to utilize erlotinib, afatinib, and gefitinib in egfr positive nsclc
-
8:11
advances in frontline therapy for egfr nsclc
-
5:10
sequencing egfr-targeted therapies in nsclc
-
6:43
sequential afatinib and osimertinib in egfr mutation-positive nsclc patients: updated results
-
0:45
dr. corey langer discusses afatinib in egfr-positive nsclc